Cargando…
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
On March 11, 2020 the World Health Organization (WHO) declared the state of global pandemic caused by the new SARS-CoV-2 (COVID-19). To date, no antivirals directed against SARS-CoV-2 or effective vaccines to combat the viral infection are available. Severe acute respiratory syndrome caused by SARS-...
Autores principales: | Vitiello, Antonio, La Porta, Raffaele, Ferrara, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788318/ https://www.ncbi.nlm.nih.gov/pubmed/33460992 http://dx.doi.org/10.1016/j.mehy.2021.110486 |
Ejemplares similares
-
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022) -
The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
por: Vitiello, Antonio, et al.
Publicado: (2021) -
Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach
por: Zhou, Yu, et al.
Publicado: (2022) -
Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
por: Valentim Gonçalves, António, et al.
Publicado: (2019)